Rohit Dhall
Title | Associate Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | Neurology, College of Medicine |
---|
Division | Neurology Faculty |
---|
Address | 501 Jack Stephens Drive Mail Slot # 500 Little Rock AR 72205
|
---|
Phone | 501-686-7236 |
---|
ORCID
.gif) | 0000-0001-9436-1920  |
---|
vCard | Download vCard |
---|
|
|
|
Overview I am a neurologist with expertise in diagnosis and management of movement disorders, including parkinsonism, dystonia and tremor. My research interests focus on development of novel diagnostics and therapeutics for neurological disorders, often through large multicenter clinical trials. I am also interested in developing and improving programs delivering care to neurological patients.
Biography Director of Neurodegenerative Disorders
Medical Director, Clinical Trials Innovation Unit
All India Institute of Medical Sciences, India | MBBS (MD) | 12/2000 | Medicine, Surgery | Univ. of Texas at Houston, School of Public Health, Houston, TX | MSPH | 12/2008 | Epidemiology | Univ. of Alabama at Birmingham, Birmingham, AK | Residency training | 07/2007 | Neurology | Univ. of Alabama at Birmingham, Birmingham, AL | Fellowship Training | 07/2009 | Movement Disorders and Deep Brain Stimulation | American Association of Physician Leaders | Certified Physician Executive | 11/2019 | Physician Leadership |
Research Funds M15-736 (DHALL, ROHIT)Sep 18, 2020 AbbVie Inc A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients (260684) Role: Principal Investigator |
| ALXN1210-MG-306 (DHALL, ROHIT)Sep 9, 2020 Alexion Pharmaceuticals - Pass Through: Syneos Health A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naive Adult Patients With Generalized Myasthenia Gravis (261071) Role: Principal Investigator |
| NLY01-PD-1, (DHALL, ROHIT)Jun 11, 2020 Neuraly - Pass Through: Rho, Inc Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of 36 Weeks of Treatment with NLY01 in Early-Stage Parkinson's Disease (260593) Role: Principal Investigator |
| IPX203-B16-03 (DHALL, ROHIT)Dec 9, 2019 Syneos Health AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS (IRB 239627) Role: Principal Investigator |
| Study 003 (DHALL, ROHIT)Oct 25, 2019 - Oct 29, 2024 Global Kinetics Corporation Ltd. Utilization of Target Ranges to Treat Patients with Parkinson’s Disease by Objective Measurement Using the Personal KinetiGraph® (PKG®) compared to Standard of Care Assessment (TARGET-PD)- A Randomized Controlled Trial (IRB 250009) Role: Principal Investigator |
| IPX203-B16-02 (DHALL, ROHIT)May 15, 2019 Impax Laboratories, Inc. A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS (228747) Role: Principal Investigator |
| IRB # 228403 (DHALL, ROHIT)Jan 8, 2019 Cala Health, Inc PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403) Role: Principal Investigator |
| P2B001-003 (DHALL, ROHIT)Aug 16, 2018 Pharma Two B - Pass Through: Pharmaceutical Research Associates, Inc. Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER. Role: Principal Investigator |
| TOZ-CL06 (DHALL, ROHIT)Aug 8, 2017 Biotie Therapies Inc. A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off” Role: Principal Investigator |
| RVT-102-2003 (DHALL, ROHIT)Jul 28, 2017 Axovant Sciences, Ltd. An open-label study of nelotanserin in patients with Lewy body dementia who have frequent visual hallucinations or REM sleep behaviors Role: Principal Investigator |
| RVT-102-2002 (DHALL, ROHIT)May 17, 2017 Axovant Sciences, Ltd. a Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) and Parkingson's Disease Dementia (PDD) who have REM Sleep behavior disorder (RBD) Role: Principal Investigator |
| IPX203-B16-01 (DHALL, ROHIT)Mar 29, 2017 Impax Laboratories, Inc. A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson’s Disease 205998 Role: Principal Investigator |
Outreach Bibliographic The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Isaacson SH, Peckham E, Tse W, Waln O, Way C, Petrossian MT, Dahodwala N, Soileau MJ, Lew M, Dietiker C, Luthra N, Agarwal P, Dhall R, Morgan J, Calakos N, Zesiewicz TA, Shamim EA, Kumar R, LeWitt P, Shill HA, Simmons A, Pagan FL, Khemani P, Tate J, Maddux B, Luo L, Ondo W, Hallett M, Rajagopal A, Chidester P, Rosenbluth KH, Delp SL, Pahwa R. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. Tremor Other Hyperkinet Mov (N Y). 2020 Aug 14; 10:29. PMID: 32864188.
-
Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 02; 71:4-10. PMID: 31927343.
-
Mirzadeh Z, Chen T, Chapple KM, Lambert M, Karis JP, Dhall R, Ponce FA. Procedural Variables Influencing Stereotactic Accuracy and Efficiency in Deep Brain Stimulation Surgery. Oper Neurosurg (Hagerstown). 2019 07 01; 17(1):70-78. PMID: 30339204.
-
Pahwa R, Dhall R, Ostrem J, Gwinn R, Lyons K, Ro S, Dietiker C, Luthra N, Chidester P, Hamner S, Ross E, Delp S. An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor. Neuromodulation. 2019 Jul; 22(5):537-545. PMID: 30701655.
-
Santiago A, Langston JW, Gandhy R, Dhall R, Brillman S, Rees L, Barlow C. Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic. J Parkinsons Dis. 2019; 9(1):207-219. PMID: 30412506.
-
Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations. Parkinsons Dis. 2018; 2018:9763057. PMID: 30425824.
-
Chen T, Mirzadeh Z, Chapple KM, Lambert M, Shill HA, Moguel-Cobos G, Tröster AI, Dhall R, Ponce FA. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2018 03 16; 130(1):109-120. PMID: 29547091.
-
Lieberman A, Deep A, Shi J, Dhall R, Shafer S, Moguel-Cobos G, Dhillon R, Frames CW, McCauley M. Downward finger displacement distinguishes Parkinson disease dementia from Alzheimer disease. Int J Neurosci. 2018 Feb; 128(2):151-154. PMID: 28911255.
-
Leehey M, Luo S, Sharma S, Wills AA, Bainbridge JL, Wong PS, Simon DK, Schneider J, Zhang Y, Pérez A, Dhall R, Christine CW, Singer C, Cambi F, Boyd JT. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology. 2017 Oct 24; 89(17):1789-1794. PMID: 28972194.
-
Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017 Sep 12; 89(11):1152-1161. PMID: 28814455.
-
Ho AL, Ali R, Connolly ID, Henderson JM, Dhall R, Stein SC, Halpern CH. Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis. J Neurol Neurosurg Psychiatry. 2018 07; 89(7):687-691. PMID: 28250028.
-
Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE. Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract. 2017 Feb; 7(1):86-93. PMID: 28243505.
-
Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127. PMID: 27911341.
-
Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50. PMID: 27380342.
-
Dhall R, Kreitzman DL. Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology. 2016 Apr 05; 86(14 Suppl 1):S13-24. PMID: 27044646.
-
Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016 07; 22(7):590-8. PMID: 26886406.
-
Chen T, Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. "Asleep" deep brain stimulation for essential tremor. J Neurosurg. 2016 Jun; 124(6):1842-9. PMID: 26613177.
-
Mirzadeh Z, Chapple K, Lambert M, Evidente VG, Mahant P, Ospina MC, Samanta J, Moguel-Cobos G, Salins N, Lieberman A, Tröster AI, Dhall R, Ponce FA. Parkinson's disease outcomes after intraoperative CT-guided "asleep" deep brain stimulation in the globus pallidus internus. J Neurosurg. 2016 Apr; 124(4):902-7. PMID: 26452116.
-
Augustine EF, Pérez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O. Sex Differences in Clinical Features of Early, Treated Parkinson's Disease. PLoS One. 2015; 10(7):e0133002. PMID: 26171861.
-
Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, Walker H, Russell DS, Christine CW, Dhall R, Singer C, Bodis-Wollner I, Hamill R, Truong D, Mari Z, Glazmann S, Huang M, Houston E, Simuni T. Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease. Mov Disord Clin Pract. 2015 Dec; 2(4):371-378. PMID: 28393083.
-
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015 Aug; 14(8):795-803. PMID: 26116315.
-
Pan D, Dhall R, Lieberman A, Petitti DB. A mobile cloud-based Parkinson's disease assessment system for home-based monitoring. JMIR Mhealth Uhealth. 2015 Mar 26; 3(1):e29. PMID: 25830687.
-
Lieberman A, Deep A, Dhall R, Tran A, Liu MJ. Early Freezing of Gait: Atypical versus Typical Parkinson Disorders. Parkinsons Dis. 2015; 2015:951645. PMID: 25785228.
-
Fang JY, Pérez A, Christine CW, Leehey M, Aminoff MJ, Boyd JT, Morgan JC, Dhall R, Nicholas AP, Bodis-Wollner I, Zweig RM, Goudreau JL. Parkinson's disease severity and use of dopaminergic medications. Parkinsonism Relat Disord. 2015 Mar; 21(3):297-9. PMID: 25541182.
-
Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. PLoS One. 2014; 9(12):e112287. PMID: 25486269.
-
Mirzadeh Z, Chapple K, Lambert M, Dhall R, Ponce FA. Validation of CT-MRI fusion for intraoperative assessment of stereotactic accuracy in DBS surgery. Mov Disord. 2014 Dec; 29(14):1788-95. PMID: 25377213.
-
Lieberman A, Dhall R, Salins N, Sadreddin A, Moguel-Cobos G, Karis J, Krishnamurthi N. Finger displacement in Parkinson disease: up? down? sideways? Int J Neurosci. 2014 May; 124(5):339-43. PMID: 24053160.
-
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 08; 383(9916):533-40. PMID: 24183563.
-
Lieberman A, Dhall R, Dhanani S, Salins N, Sadreddin A, Moguel-Cobos G, Pan D, Santiago A, Prigatano G, Krishnamurthi N, Troster A. Distinguishing the tremor of Parkinson's disease from essential tremor: finger displacement. Int J Neurosci. 2014 Mar; 124(3):175-80. PMID: 23879402.
-
Elm JJ. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012 Oct; 27(12):1513-21. PMID: 23079770.
-
Lieberman A, Krishnamurthi N, Dhall R, Santiago A, Moguel-Cobos G, Sadreddin A, Husain S, Salins N, Pan D. A simple question about falls to distinguish balance and gait difficulties in Parkinson's disease. Int J Neurosci. 2012 Dec; 122(12):710-5. PMID: 22784291.
-
Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008 Sep; 38(3):1101-7. PMID: 18720508.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2008 | 1 | 2012 | 2 | 2013 | 3 | 2014 | 3 | 2015 | 7 | 2016 | 3 | 2017 | 6 | 2018 | 2 | 2019 | 4 | 2020 | 1 |
To return to the timeline, click here.
|
Dhall's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|